molecules of the month


oral HBV antigen inhibitor

Ph. I candidate for hepatitis B

SAR opt. of a previously disclosed inhibitor

Bioorganic Med. Chem. Lett.

WuXi AppTec, Shanghai, CN

GST-HG131 chemical structure oral HBV antigen inhibitor - WuXi AppTec, Shanghai, CN
5 mins read

Context. GST-HG131 (WuXi AppTec) is an oral hepatitis B virus (HBV) inhibitor which lowers hepatitis B antigen (HBsAg) levels which entered clinical development in Chinese subjects for chronic hepatitis B infection. Despite the significant research strides made in the elucidation of the biology of HBV, chronic HBV infection continues to remain a significant global health challenge, with functional cure rates of current treatments at <30%. Although no current treatment eradicates the virus, there is an effective vaccine available to prevent infection. One potential reason why new HBV therapies are often tested in China is that the adult vaccination rate there is only 26%. HBV antigen loss and seroconversion are key endpoints of chronic HBV treatment, and HBsAg itself can suppress…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: